DDInter1533 DDInter927
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Promethazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propiomazine
Promethazine {u} (Compound) resembles {v} (Compound) Chlorprothixene
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Promethazine {u} (Compound) binds {v} (Gene) CALM3
Promethazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Promethazine {u} (Compound) causes {v} (Side Effect) Decreased appetite
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Promethazine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Promethazine (Compound) resembles Ethopropazine (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Promethazine (Compound) resembles Chlorprothixene (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Promethazine (Compound) binds CALM3 (Gene)
Promethazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Promethazine (Compound) causes Decreased appetite (Side Effect)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Promethazine may lead to a major life threatening interaction when taken with Toremifene